Efficacy and Safety of JHG002 for Chronic Temporomandibular Joint Dysfunction: A Multicenter Randomized Controlled Trial

• Sponsor: Jaseng Medical Foundation (Other)
• Overall Status: Completed
• CT.gov ID: NCT04087005
• Collaborator: (none)
• Enrollment: 82
• Locations: 2
• Arms: 2
• Actual Duration (Months): 9.1
• Patients Per Site: 41
• Patients Per Site Per Month: 4.5

Study Details

Study Description

Brief Summary

This study is a 2-arm parallel, assessor blinded, multi-centre, randomised controlled trial.

Condition or Disease	Intervention/Treatment	Phase
Temporomandibular Disorder	Other: hominis placental pharmacopuncture	N/A

Detailed Description

From 2 hospitals of Korean medicine, we will enrol 82 chronic TMD patients in Axis 1, Group Ⅰ according to RDC/TMD diagnostic criteria, and randomly allocate 41 patients each to an HPP group and a physical therapy (PT) group. Treatment will be administered in 10 rounds, after which there will be 4 follow-up visits (6, 9, 13, and 25 weeks from baseline). The primary end point is 6 weeks after baseline, and the primary outcome is the difference in Visual analogue scale (VAS) score for temporomandibular pain between baseline and Week 6. Secondary outcomes will be Numeric rating scale (NRS) scores for temporomandibular pain and discomfort, temporomandibular joint range of motion, Korean version of Beck's Depression Index-Ⅱ(K-BDI-II), Jaw Functional Limitation Scale (JFLS), Patien Global Impression of Change(PGIC), and quality of life. Using data on adverse events and cost-effectiveness in the two groups, we will perform a safety assessment and a cost-effectiveness analysis (economic assessment).

Study Design

• Study Type: Interventional
• Actual Enrollment: 82 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Efficacy and Safety of JHG002(Hominis Placenta, 紫河車) Therapy for Chronic Temporomandibular Joint Dysfunction: A Multicenter Randomized Controlled Trial)
• Actual Study Start Date: Oct 17, 2019
• Actual Primary Completion Date: Jul 21, 2020
• Actual Study Completion Date: Jul 21, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Hominis placental pharmacopuncture The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.	Other: hominis placental pharmacopuncture; Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
Active Comparator: Transcutaneous electrical nerve stimulation The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).	Other: hominis placental pharmacopuncture; Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.

Outcome Measures

Primary Outcome Measures

1. The difference in visual analogue scale (VAS) of temporomandibular pain [Week 6]

   The primary outcome is the difference in VAS for TMJ pain between baseline and the primary end point (Week 6). VAS is an assessment index in which the patient records their pain on a 100mm line from 'no pain' at one end, and 'the most severe pain imaginable' at the other end.

Secondary Outcome Measures

1. Numeric rating scale (NRS) of TMJ pain and discomfort [Week 6]

   The extent of TMJ pain and discomfort in the last week will be assessed using NRS. NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participant is asked to report their TMJ pain and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.

2. TMJ range of motion [Week 6]

   A Therabite Range of Motion Ruler will be used to measure the range of TMJ mouth opening and excursive movement; the measurement method will follow the guidelines provided by the International RDC/TMD Consortium.

3. Korean version of Beck's Depression Index-Ⅱ (K-BDI-Ⅱ) [Week 6]

   The BDI-Ⅱ is an index for diagnosing depression, consisting of 21 questions related to sadness, guilt, suicidal ideation, and loss of interest. In this study, we will use the K-BDI-II, which has been demonstrated to be valid and reliable by a Korean research group.

4. Jaw Functional Limitation Scale (JFLS) [Week 6]

   The JFLS is an index assessing jaw function (mastication, mobility, and emotional and verbal expression) in the last month. The instrument consists of 20 questions, and each question is scored 0-10, where 0 points is 'no impairment' and 10 points is 'very severe impairment'. In this study, we will use the official Korean version of the 20-question JFLS, which has been demonstrated to be reliable.

5. Patient Global Impression of Change (PGIC) [Week 6]

   The PGIC is an index that assesses improvements in functional limitation caused by TMD in 7 grades. Participants rate the improvement in functional limitations after treatment on a 7-point Likert scale (1=Very much improved, 4=No change, 7=Very much worse). This index was originally developed for use in Psychology, but is currently used in various other medical fields to assess improvements in pain.

6. The five level version of EuroQol-5 Dimension (EQ-5D-5L) [Week 6]

   The EQ-5D-5L is a method of indirectly calculating the weights of certain health states for quality of life after a multidimensional investigation of health states, and is the most widely used instrument for this purpose. The EQ-5D-5L consists of 5 questions about current health state (mobility, self-care, usual activities, pain, anxiety/depression), and each question is scored on a 5-point Likert scale (1=no problems, 3=moderate problems, 5=severe problems). In this study, we will use the Korean version of the EQ-5D-5L, which has been demonstrated to be valid.

7. SF-12 [Week 6]

   The SF-12 is a shortened version of the Short Form-36 Health Survey (SF-36), which is a widely used instrument to assess health-related quality of life. The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life. In this study, we will use the Korean version of the SF-12, which has been demonstrated to be reliable and valid.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients with unilateral or bilateral TMJ pain

2. Patients with VAS≥40mm for the area showing TMJ pain (for patients with bilateral pain, the side with worse pain)

3. Patients complaining of persistent of sporadic TMJ pain for at least 3 months

4. Patients diagnosed as myofascial TMD (Axis I: Group 1) based on the RDC/TMD diagnostic criteria[5]

5. Patients aged 19-70 years on the date they sign the consent form

6. Patients who provide consent to participate in the trial and return the informed consent form

Exclusion Criteria:

1. Patients whose current pain episode developed or worsened because of a road traffic accident or traumatic injury

2. Patients diagnosed in Group 2 or 3 of Axis I based on the RDC/TMD diagnostic criteria

3. Patients who have undergone surgery related to the TMJ

4. Patients with other chronic disease that could interfere with interpretation of the treatment effects or outcomes (e.g., rheumatoid arthritis, neoplastic disease, stroke, or myocardial infarction)

5. Patients currently taking steroids, immunosuppressants, psychiatric drugs, or other drugs that could affect the study results

6. Patients who have received HPP within the last month, or who have taken drugs that could affect pain, such as NSAIDs, within the last week

7. Pregnant or breastfeeding women

8. Patients who have finished participation in another clinical trial within the last month, who participated in another trial within 6 months of selection, or who are planning to participate in another clinical trial during the follow-up period

9. Patients with a history of hypersensitivity after HPP

10. Diabetic patients with uncontrolled blood glucose (fasting blood glucose ≥180mg/dl)

11. Patients with AST (GOT) or ALT (GPT) at least 2 times the normal range at the testing centre

12. Patients with creatinine at least 2 times the normal range at the testing centre

13. Patients suspected to have organic disease

14. Patients with cardiac, hepatic, renal, or other serious complications

15. Patients with psychogenic disease

16. Patients who are unable to receive pharmacopuncture due to e.g., inflammation or a wound at the relevant acupoints

17. Other patients whose participation in the trial is judged by a researcher to be problematic

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Jaseng Hospital of Korean Medicine	Seoul	Gangnam-Gu	Korea, Republic of	135-896
2	Kyung Hee University Hospital at Gangdong	Seoul		Korea, Republic of

Sponsors and Collaborators

• Jaseng Medical Foundation

Investigators

• Principal Investigator: In-Hyuk Ha, Jaseng Hospital of Korean Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: In-Hyuk Ha, KMD, Director, Jaseng Medical Foundation
• ClinicalTrials.gov Identifier: NCT04087005
• Other Study ID Numbers: JS-CT-2017-04
• First Posted: Sep 12, 2019
• Last Update Posted: Jun 2, 2021
• Last Verified: May 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome; Joint Diseases

Study Results

No Results Posted as of Jun 2, 2021